{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:46:56Z","timestamp":1782798416515,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People\u2019s Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Multi-target drugs frequently exhibit tissue-dependent pharmacological directions: the same compound may promote a biological process in one organ while driving its functional opposite in another. Tamoxifen antagonizes estrogen receptors in breast tissue yet activates them in the endometrium; non-selective NSAIDs reduce inflammation at injury sites while damaging the gastric mucosa. Each phenomenon has been explained by drug-specific mechanisms, but no unifying principle predicts when or why such direction reversal occurs. Here we propose tissue-autonomous pharmacological direction (TAPD): when a compound simultaneously engages two functionally opposing target classes, its net pharmacological direction in any tissue is determined primarily by which class is more abundantly expressed locally. We formalize this principle through the Tissue Direction Index (TDI), a dimensionless metric (0\u20131) integrating binding affinity with tissue-specific expression data from transcriptomic atlases. As proof of concept, we show that bridging metabolites from traditional Chinese botanical drugs with uniform molecular-level coagulation bias undergo substantial hemostatic direction shifts between gastrointestinal and brain tissue (4.6-fold Hemostatic Index change, driven predominantly by expression differences), with two metabolites achieving complete direction reversal. We then discuss how TAPD complements existing models of tissue-selective drug effects, including SERMs, NSAIDs, kinase inhibitors, and immunomodulators, and outline translational applications in drug repurposing, predictive toxicology, and patient-specific pharmacological prediction.<\/jats:p>","DOI":"10.3389\/fphar.2026.1870571","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:39:43Z","timestamp":1782797983000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tissue-autonomous pharmacological direction: how target expression landscapes convert balanced compounds into tissue-selective agents"],"prefix":"10.3389","volume":"17","author":[{"given":"Huizhen","family":"Chen","sequence":"first","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Chen","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhong","family":"Wang","sequence":"additional","affiliation":[{"name":"King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"Barab\u00e1si","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1021\/acs.chemrestox.5b00407","article-title":"Toxicology strategies for drug discovery: present and future","volume":"29","author":"Blomme","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1021\/acs.jcim.0c01227","article-title":"Toward an understanding of pan-assay interference compounds and promiscuity: a structural perspective on binding modes","volume":"61","author":"Bolz","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"B6","first-page":"297","article-title":"Systems approaches to polypharmacology and drug discovery","volume":"13","author":"Boran","year":"2010","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"B7","article-title":"An expression-weighted docking framework for exploring tissue-dependent direction of multi-target compounds, illustrated on hemostatic regulation. (under review)","author":"Chen","year":"2026","journal-title":"BMC Complement. Med. Ther"},{"key":"B8","volume-title":"Pharmacopoeia of the People\u2019s Republic of China","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The drug repurposing hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"Csermely","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nrd1225","article-title":"COX-2 and beyond: approaches to prostaglandin inhibition in human disease","volume":"2","author":"FitzGerald","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx consortium atlas of genetic regulatory effects across human tissues","volume":"369","year":"2020","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/jnci\/djk062","article-title":"SERMs: meeting the promise of multifunctional medicines","volume":"99","author":"Jordan","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nbt.1678","article-title":"Epigenetic modifications as therapeutic targets","volume":"28","author":"Kelly","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s12539-019-00327-w","article-title":"An overview of scoring functions used for protein-ligand interactions in molecular docking","volume":"11","author":"Li","year":"2019","journal-title":"Interdiscip. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1038\/s41467-019-09799-2","article-title":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","volume":"10","author":"Menden","year":"2019","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"B28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e27041","DOI":"10.7554\/eLife.27041","article-title":"The human cell atlas","volume":"6","author":"Regev","year":"2017","journal-title":"Elife"},{"key":"B30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.7326\/0003-4819-137-9-200211050-00035","article-title":"Cardioselective beta-blockers in patients with reactive airway disease","volume":"137","author":"Salpeter","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1210\/er.2003-0023","article-title":"Coregulator function: a key to understanding tissue specificity of selective receptor modulators","volume":"25","author":"Smith","year":"2004","journal-title":"Endocr. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","article-title":"Mechanism of action of nonsteroidal anti-inflammatory drugs","volume":"104","author":"Vane","year":"1998","journal-title":"Am. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"12964","DOI":"10.1039\/C6CP01555G","article-title":"Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes","volume":"18","author":"Wang","year":"2016","journal-title":"Phys. Chem. Chem. Phys."},{"key":"B42","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1870571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:39:45Z","timestamp":1782797985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1870571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":43,"alternative-id":["10.3389\/fphar.2026.1870571"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1870571","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1870571"}}